Research programme: inhaled therapeutics - MannKind/Receptor Life Sciences

Drug Profile

Research programme: inhaled therapeutics - MannKind/Receptor Life Sciences

Alternative Names: Epinephrine Technosphere®; Palonosetron Technosphere®; Treprostinil Technosphere®

Latest Information Update: 23 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MannKind Corporation; Receptor Life Sciences
  • Class Antiarrhythmics; Antiemetics; Antihypertensives; Antihypotensives; Benzene derivatives; Bronchodilators; Catecholamines; Ethanolamines; Isoquinolines; Prostaglandins; Quinuclidines; Small molecules; Vasodilators
  • Mechanism of Action Adrenergic receptor agonists; Epoprostenol receptor agonists; Platelet aggregation inhibitors; Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Research Anaphylaxis; Nausea and vomiting; Pulmonary arterial hypertension

Most Recent Events

  • 07 Aug 2017 MannKind intends to file an IND application with the US FDA for Treprostinil Technosphere for Pulmonary arterial hypertension
  • 05 Jun 2017 Research programme: inhaled therapeutics - MannKind/Receptor Life Sciences is available for licensing as of 05 Jun 2017. http://www.mannkindcorp.com
  • 21 Jan 2016 MannKind and Receptor Life Sciences agree to co-develop inhaled therapeutics for Pain, Neurological disorders and Inflammation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top